clinical trial | Q30612 |
P3098 | ClinicalTrials.gov ID | NCT02443155 |
P6099 | clinical trial phase | phase II clinical trial | Q42824440 |
P17 | country | Canada | Q16 |
Norway | Q20 | ||
Republic of Ireland | Q27 | ||
Spain | Q29 | ||
United States of America | Q30 | ||
Belgium | Q31 | ||
Finland | Q33 | ||
Sweden | Q34 | ||
Denmark | Q35 | ||
Italy | Q38 | ||
Poland | Q36 | ||
Austria | Q40 | ||
Portugal | Q45 | ||
United Kingdom | Q145 | ||
Ukraine | Q212 | ||
Serbia | Q403 | ||
Israel | Q801 | ||
P582 | end time | 2018-08-31 | |
P4135 | maximum age | 45 | |
P1050 | medical condition | diabetes | Q12206 |
P2899 | minimum age | 18 | |
P1132 | number of participants | 308 | |
P4844 | research intervention | liraglutide | Q2526479 |
P6153 | research site | Novo Nordisk | Q818846 |
P580 | start time | 2015-11-10 | |
P8363 | study type | interventional study | Q78089383 |
P1476 | title | A Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Multi-centre Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function |
Search more.